Get the Stockscreener App
2.29
0.00%
0.00
After Hours:
2.30
0.010
+0.44%
Spero Therapeutics Inc stock is traded at $2.29, with a volume of 178.37K.
It is up +0.00% in the last 24 hours and down -0.43% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.29
Open:
$2.26
24h Volume:
178.37K
Relative Volume:
0.62
Market Cap:
$129.02M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
229.00
EPS:
0.01
Net Cash Flow:
$28.98M
1W Performance:
+3.62%
1M Performance:
-0.43%
6M Performance:
+6.51%
1Y Performance:
+197.33%
1-Day Range:
$2.22
$2.30
1-Week Range:
$2.11
$2.305
52-Week Range:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.29 | 129.02M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0% - MarketBeat
SPRO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock sustain margin levels2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Patterns Watch: Can Spero Therapeutics Inc ride the EV waveJuly 2025 Intraday Action & Stock Portfolio Risk Control - baoquankhu1.vn
Aug PostEarnings: Can Spero Therapeutics Inc sustain earnings growth2025 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
Valuation Update: Is Spero Therapeutics Inc stock showing strong momentum2025 Market Overview & Daily Volume Surge Signals - baoquankhu1.vn
Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock - simplywall.st
Is Spero Therapeutics Inc. a good stock for dollar cost averaging2025 Price Targets & Weekly High Potential Stock Alerts - mfd.ru
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha
Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock - MarketBeat
Keutzer, Spero Therapeutics COO, sells $44k in shares - Investing.com
Spero Therapeutics CEO sells $207k in stock By Investing.com - Investing.com Canada
Keutzer, Spero Therapeutics COO, sells $44k in shares By Investing.com - Investing.com Canada
Spero Therapeutics CEO sells $207k in stock - Investing.com
Aug Breakouts: What drives Spero Therapeutics Incs stock priceEarnings Summary Report & Safe Entry Zone Tips - baoquankhu1.vn
Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Spero therapeutics exec Rajavelu sells $40k in shares By Investing.com - Investing.com Australia
Spero therapeutics exec Rajavelu sells $40k in shares - Investing.com
Spero Therapeutics announces board resignation and SEC investigation closure By Investing.com - Investing.com South Africa
Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks
SEC ends Spero Therapeutics (NASDAQ: SPRO) probe as director steps down - Stock Titan
SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures - marketscreener.com
SEC Enforcement Action against Former Spero Executives: Individual Liability for Misleading FDA-Related Disclosures - Foley & Lardner LLP
SEC Settlement Resolves Past Disclosure Issues for Spero Therapeutics - AD HOC NEWS
Spero Therapeutics announces inducement grant under Nasdaq listing rule - MSN
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings - Law360
Momentum Shift: What is Spero Therapeutics Incs valuation compared to sector2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Insider Buy: Is Spero Therapeutics Inc stock overvalued by current metricsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - Bộ Nội Vụ
Stock Market Recap: Will Spero Therapeutics Inc. stock reach all time highs in 20252025 Trading Volume Trends & Stock Portfolio Risk Management - Bộ Nội Vụ
Spero Therapeutics (NASDAQ:SPRO) Raised to "Buy" at Wall Street Zen - MarketBeat
Will Spero Therapeutics Inc. (2HA) stock sustain bullish trend into 2025 - ulpravda.ru
Is Spero Therapeutics Inc. (2HA) stock protected from inflationJuly 2025 Levels & Fast Gain Swing Trade Alerts - ulpravda.ru
Will Spero Therapeutics Inc. stock benefit from upcoming earnings reports2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
3 Promising Penny Stocks With Market Caps Up To $300M - simplywall.st
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold - MarketBeat
What analysts say about Spero Therapeutics Inc stockLong-Term Growth Stocks & Free Unmatched Market Gains - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest - MarketBeat
Book value per share of Spero Therapeutics, Inc. – BER:2HA - TradingView — Track All Markets
Spero Therapeutics (STU:2HA) EV-to-OCF : -2.75 (As of Dec. 24, 2025) - GuruFocus
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Growth Oriented Trade Recommendations - Улправда
Stop Loss: Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Reliable Price Breakout Signals - ulpravda.ru
GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections - Contemporary OB/GYN
GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks
Spero Therapeutics Announces NDA Resubmission for Tebipenem HBr - TradingView — Track All Markets
Spero Therapeutics Announces GSK's NDA Resubmission for Tebipenem HBr, Triggering $25 Million Milestone Payment - Quiver Quantitative
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):